Retrospective study comparing low-dose versus standard dose of bortezomib in patients with multiple myeloma

Retrospective study comparing low-dose versus standard dose of bortezomib in patients with multiple myeloma

INTRODUCTION Bortezomib is a selective inhibitor of the proteosoma that is used in multiple myeloma. In combination with other antineoplastic drugs, it has a well-documented impact in progression-free survival rates and overall survival rates with standard doses (1.3-1.5 mg/m2). However, up to 88%...

Full description

Bibliographic Details
Main Authors:	Marcela Espinoza Zelada, Nicole Befferman Cordova, Mauricio Ocqueteau Tachin, Pablo Ramírez Villanueva, Mauricio Galleguillos M., Mauricio Sarmiento Maldonado
Format:	Article
Language:	English
Published:	Medwave Estudios Limitada 2015-03-01
Series:	Medwave
Online Access:	http://www.medwave.cl/link.cgi/Medwave/Estudios/Investigacion/6098

Similar Items

Response and survival in acute myeloid leukemia patients not candidates to transplantation treated with azacitidine versus palliative treatment: a retrospective study
by: Mauricio Sarmiento Maldonado, et al.
Published: (2015-08-01)

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy
by: María-Victoria Mateos, et al.
Published: (2014-06-01)

Treatment Outcomes with Reduced-Dose Bortezomib in Adult Patients with Multiple Myeloma: A Single-Center Experience
by: Jeremiah R. Vallente, et al.
Published: (2022-07-01)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
by: Se Ryeon Lee, et al.
Published: (2019-11-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01)

Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
by: Su-Hee Cho, et al.
Published: (2019-05-01)

TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB
by: Veronika Kodre, et al.
Published: (2008-04-01)

Bortezomib in the management of multiple myeloma
by: Jacob P Laubach, et al.
Published: (2009-09-01)

Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
by: Dong Liang, et al.
Published: (2024-09-01)

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
by: Utkarsh Goel, et al.
Published: (2024-03-01)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
by: Mauricio Sarmiento Maldonado, et al.
Published: (2017-12-01)

A real life use of ruxolitinib in patients with acute and chronic graft versus host disease refractory to corticosteroid treatment in Latin American patients
by: Mauricio Sarmiento, et al.
Published: (2021-07-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Bortezomib for the treatment of multiple myeloma patients
by: C Green, et al.
Published: (2009-06-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
by: Meletios A. Dimopoulos, et al.
Published: (2015-01-01)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
by: Angelica Ferro, et al.
Published: (2023-02-01)

Clinical outcomes of bortezomib-based therapy in myeloma.
by: Faouzi Djebbari, et al.
Published: (2018-01-01)

Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontiﬁcia Universidad Católica de Chile
by: Pablo Ramirez, et al.
Published: (2015-06-01)

Comment on “Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma”
by: Simon J. Harrison, et al.
Published: (2015-09-01)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
by: Andrew Spencer, et al.
Published: (2018-12-01)

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
by: Rahul Banerjee, et al.
Published: (2023-11-01)

Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
by: Edwards, C, et al.
Published: (2007)

Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011-02-01)

Effective response with bortezomib retreatment in relapsed multiple myeloma
by: Christian Taverna, et al.
Published: (2012-04-01)

Iron increases the susceptibility of multiple myeloma cells to bortezomib
by: Alessandro Campanella, et al.
Published: (2013-06-01)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
by: Joseph Han, et al.
Published: (2023-07-01)

A feline case of multiple myeloma treated with bortezomib
by: Hiroyuki Tani, et al.
Published: (2022-11-01)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01)

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
by: Ye Z, et al.
Published: (2019-05-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01)

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
by: Philippe Moreau, et al.
Published: (2008-12-01)

Low-dose versus standard-dose azithromycin for treatment of yaws
by: Lenka Mikalová, et al.
Published: (2018-04-01)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
by: Paweł Robak, et al.
Published: (2020-01-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma
by: Chi Zhang, et al.
Published: (2023-11-01)

The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
by: Nicholas Nikesitch, et al.
Published: (2021-12-01)